Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid

M. Stiborová, E. Frei, VM. Arlt, HH. Schmeiser,

. 2014 ; 44 (2) : 135-45.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc15008536

UNLABELLED: 1. Aristolochic acid I (AAI) is the predominant component in plant extract of Aristolochia genus that is involved in development of aristolochic acid nephropathy, Balkan endemic nephropathy and urothelial cancer. The diseases do not develop in all individuals exposed to AAI and patients exhibit different clinical outcomes. Differences in the activities of enzymes catalyzing the metabolism of AAI might be one of the reasons for this individual susceptibility. 2. Understanding which human enzymes are involved in reductive activation of AAI generating AAI-DNA adducts, and/or its detoxication to the O-demethylated metabolite, aristolochic acid Ia (AAIa), is necessary in the assessment of the susceptibility to this compound. 3. This review summarizes the results of the latest studies utilizing genetically engineered mouse models to identify which human and rodent enzymes catalyze the reductive activation of AAI to AAI-DNA adducts and its oxidative detoxication to AAIa in vivo. 4. The use of hepatic cytochrome P450 (Cyp) reductase null (HRN) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes, Cyp1a1((-/-)), Cyp1a2((-/-)) single-knockout, Cyp1a1/1a2((-/-)) double-knockout and CYP1A-humanized mice revealed that mouse and human CYP1A1 and 1A2, besides mouse NAD(P)H: quinone oxidoreductase, were involved in the activation of AAI but CYP1A1 and 1A2 also oxidatively detoxified AAI.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008536
003      
CZ-PrNML
005      
20171215201513.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/00498254.2013.848310 $2 doi
035    __
$a (PubMed)24152141
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University , Prague , Czech Republic .
245    10
$a Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid / $c M. Stiborová, E. Frei, VM. Arlt, HH. Schmeiser,
520    9_
$a UNLABELLED: 1. Aristolochic acid I (AAI) is the predominant component in plant extract of Aristolochia genus that is involved in development of aristolochic acid nephropathy, Balkan endemic nephropathy and urothelial cancer. The diseases do not develop in all individuals exposed to AAI and patients exhibit different clinical outcomes. Differences in the activities of enzymes catalyzing the metabolism of AAI might be one of the reasons for this individual susceptibility. 2. Understanding which human enzymes are involved in reductive activation of AAI generating AAI-DNA adducts, and/or its detoxication to the O-demethylated metabolite, aristolochic acid Ia (AAIa), is necessary in the assessment of the susceptibility to this compound. 3. This review summarizes the results of the latest studies utilizing genetically engineered mouse models to identify which human and rodent enzymes catalyze the reductive activation of AAI to AAI-DNA adducts and its oxidative detoxication to AAIa in vivo. 4. The use of hepatic cytochrome P450 (Cyp) reductase null (HRN) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes, Cyp1a1((-/-)), Cyp1a2((-/-)) single-knockout, Cyp1a1/1a2((-/-)) double-knockout and CYP1A-humanized mice revealed that mouse and human CYP1A1 and 1A2, besides mouse NAD(P)H: quinone oxidoreductase, were involved in the activation of AAI but CYP1A1 and 1A2 also oxidatively detoxified AAI.
650    _2
$a zvířata $7 D000818
650    _2
$a kyseliny aristolochové $x metabolismus $x farmakokinetika $x toxicita $7 D034341
650    _2
$a karcinogeny $x metabolismus $x farmakokinetika $7 D002273
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $x metabolismus $7 D019363
650    _2
$a cytochrom P-450 CYP1A2 $x genetika $x metabolismus $7 D019388
650    _2
$a adukty DNA $x metabolismus $7 D018736
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a enzymy $x genetika $x metabolismus $7 D004798
650    _2
$a lidé $7 D006801
650    12
$a metabolická inaktivace $7 D008658
650    _2
$a nemoci ledvin $x chemicky indukované $7 D007674
650    _2
$a myši $7 D051379
650    12
$a myši knockoutované $7 D018345
650    _2
$a NAD(P)H dehydrogenasa (chinon) $x antagonisté a inhibitory $7 D016660
650    _2
$a NADPH-cytochrom c-reduktasa $x genetika $x metabolismus $7 D009251
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Frei, Eva
700    1_
$a Arlt, Volker M. $7 xx0074763 $4
700    1_
$a Schmeiser, Heinz H
773    0_
$w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 44, č. 2 (2014), s. 135-45
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24152141 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150401095532 $b ABA008
999    __
$a ok $b bmc $g 1065809 $s 891336
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 44 $c 2 $d 135-45 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
LZP    __
$a Pubmed-20150306

Find record

Citation metrics

Archiving options